GlassScriptPhysician profile
David C Kung
NPI 1134474653
$4,552.30
in general payments reported to CMS, 2019-2025
21 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,644 · 2020: $348 · 2021: $664 · 2022: $584 · 2023: $674 · 2024: $283 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.13 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,460.66 | 2019-2025 | |
| Amgen INC. | $846.09 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $817.09 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $427.44 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $232.50 | 2019-2020 | |
| Horizon Therapeutics Plc | $130.80 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.65 | 2019-2024 | Orencia |
| Fresenius Kabi USA, LLC | $85.26 | 2024-2025 | Tyenne, Idacio |
| Celgene Corporation | $67.17 | 2019 | |
| Radius Health, INC. | $49.36 | 2019 | |
| Glaxosmithkline, LLC. | $44.50 | 2019-2021 | |
| Genentech USA, INC. | $44.04 | 2019 | |
| Sobi, INC | $41.66 | 2019 | |
| Genzyme Corporation | $31.78 | 2019-2025 | |
| Abbott Laboratories | $30.28 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $24.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.57 | 2021 | |
| Vertiflex, INC. | $14.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.